Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Expression of the p53 Family in Lung Cancer

HIDETAKA URAMOTO, KENJI SUGIO, TSUNEHIRO OYAMA, SHOJI NAKATA, KENJI ONO, TADAHIRO NOZOE and KOSEI YASUMOTO
Anticancer Research May 2006, 26 (3A) 1785-1790;
HIDETAKA URAMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hidetaka{at}med.uoeh-u.ac.jp
KENJI SUGIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUNEHIRO OYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hidetaka{at}med.uoeh-u.ac.jp
SHOJI NAKATA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJI ONO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TADAHIRO NOZOE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSEI YASUMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: p53 is mutated in about 50% of various malignant diseases including lung cancer. The p53 family consists of p53, p73 and p63. Although transactivating protein isoforms display p53-like functions, the ΔNp73 or ΔNp63 isoforms act toward p53 in a dominantly negative way. The aim of this study was to detect p53, ΔNp73 and ΔNp63 expressions in lung cancer and to evaluate the relationship between the expression levels of the proteins and the prognosis of patients with resectable lung cancer. Materials and Methods: Immunohistochemistry was employed to analyze the protein expression of p53, ΔNp73 and ΔNp63 in paraffin-embedded tumor samples from 132 well-characterized lung cancer patients. The correlation among the expression levels of p53, ΔNp73 and ΔNp63, clinical variables and survival outcome was analyzed. Results: Positive expressions of p53, ΔNp73 and ΔNp63 were detected in the tumor cells in 52, 77 and 44 of the 132 patients, respectively (39.4%, 58.3% and 33.3%) with lung cancer. The incidence of p53 positive expression was 54.5% and 27.6% in patients with squamous cell carcinoma and adenocarcinoma, respectively (p=0.03). The incidence of a positive expression of ΔNp73 was 64.5% and 43.6% in male and female patients, respectively (p=0.03). The incidence of ΔNp63 positive expression was 68.2% and 15.8% in the patients with squamous cell carcinoma and adenocarcinoma, respectively (p<0.0001). The expressions of p53 and ΔNp63 were not found to significantly affect survival. However, lung cancer patients with a positive ΔNp73 expression had a poorer prognosis than those with a negative ΔNp73 expression. In addition, multivariate analysis indicated that a positive expression of ΔNp73 was a significantly independent factor for predicting a poor prognosis (p<0.0001, risk ratio=3.38). Conclusion: Clinical evidence that the p53 family is frequently overexpressed in lung cancer specimens, especially ΔNp63 in squamous cell carcinoma, was provided. The expression of ΔNp73 may be a useful marker for predicting a poor prognosis in resectable lung cancer. Understanding how groups of lung cancer cell genes are coordinately expressed in response to physiological, immunological and micro-environmental stimuli remains an important goal. A better understanding of the gene expression profiles of tumors may help to identify molecular targets, such as ΔNp73, for effective therapy.

  • p53
  • γNp73
  • γNp63
  • lung cancer
  • immunohistochemistry
  • prognostic factor

Footnotes

  • Abbreviations: TA, transactivating domain; IHC, immunohistochemical.

  • Received January 30, 2006.
  • Accepted March 7, 2006.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 3A
May-June 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Expression of the p53 Family in Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Expression of the p53 Family in Lung Cancer
HIDETAKA URAMOTO, KENJI SUGIO, TSUNEHIRO OYAMA, SHOJI NAKATA, KENJI ONO, TADAHIRO NOZOE, KOSEI YASUMOTO
Anticancer Research May 2006, 26 (3A) 1785-1790;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Expression of the p53 Family in Lung Cancer
HIDETAKA URAMOTO, KENJI SUGIO, TSUNEHIRO OYAMA, SHOJI NAKATA, KENJI ONO, TADAHIRO NOZOE, KOSEI YASUMOTO
Anticancer Research May 2006, 26 (3A) 1785-1790;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung
  • Google Scholar

More in this TOC Section

  • Silencing of β-TrCP2 Suppresses Growth and G1/S Cell Cycle Progression in Non-small Cell Lung Carcinoma Cells
  • Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience
  • Targeting AURKB Attenuates Tumor Growth in MYC-driven Lung Adenocarcinoma
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire